---
title: 'Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph- B-lineage
  ALL: the GIMEMA LAL2317 Phase 2 Study'
date: '2025-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40009490/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250227170931&v=2.18.0.post9+e462414
source: Blood
description: The GIMEMA LAL2317 protocol investigated the frontline chemotherapy-blinatumomab
  combination in adult Philadelphia- CD19+ B-lineage acute lymphoblastic leukemia
  (Ph- B-ALL) to improve minimal residual disease (MRD) response and clinical outcome.
  Two cycles of intravenous blinatumomab were administered after chemotherapy cycles
  3 and 6. The primary endpoint was the rate of molecular MRD negativity following
  blinatumomab 1. One hundred and forty-nine patients were enrolled (median age 41
  ...
disable_comments: true
---
The GIMEMA LAL2317 protocol investigated the frontline chemotherapy-blinatumomab combination in adult Philadelphia- CD19+ B-lineage acute lymphoblastic leukemia (Ph- B-ALL) to improve minimal residual disease (MRD) response and clinical outcome. Two cycles of intravenous blinatumomab were administered after chemotherapy cycles 3 and 6. The primary endpoint was the rate of molecular MRD negativity following blinatumomab 1. One hundred and forty-nine patients were enrolled (median age 41 ...